Plasma chromogranin-A (CgA) concentrations correlate with severe cardiovascular diseases, whereas CgAderived vasostatin-I and catestatin elicit cardiosuppression via an antiadrenergic/nitric oxide-cGMP mediated mechanism. Whether these phenomena are related is unknown. We here investigated whether and to what extent full-length CgA directly influences heart performance and may be subjected to stimuluselicited intracardiac processing. Using normotensive and hypertensive rats, we evaluated the following: 1) direct myocardial and coronary effects of full-length CgA; 2) the signal-transduction pathway involved in its action mechanism; and 3) CgA intracardiac processing after ␤-adrenergic [isoproterenol (Iso)]-and endothelin-1(ET-1)-dependent stimulation. The study was performed by using a Langendorff perfusion apparatus, Western blotting, affinity chromatography, and ELISA. We found that CgA (1-4 nM) dilated coronaries and induced negative inotropism and lusitropism, which disappeared at higher concentrations (10-16 nM). In spontaneously hypertensive rats (SHRs) , negative inotropism and lusitropism were more potent than in young normotensive rats. We found that perfusion itself, Iso-, and endothelin-1 stimulation induced intracardiac CgA processing in low-molecular-weight fragments in young, Wistar Kyoto, and SHR rats. In young normotensive and adult hypertensive rats, CgA increased endothelial nitric oxide synthase phosphorylation and cGMP levels. Analysis of the perfusate from both Wistar rats and SHRs of untreated and treated (Iso) hearts revealed CgA absence. In conclusion, in normotensive and hypertensive rats, we evidenced the following: 1) full-length CgA directly affects myocardial and coronary function by AkT/nitric oxide synthase/nitric oxide/cGMP/protein kinase G pathway; and 2) the heart generates intracardiac CgA fragments in response to hemodynamic and excitatory challenges. For the first time at the cardiovascular level, our data provide a conceptual link between systemic and intracardiac actions of full-length CgA and its fragments, expanding the knowledge on the sympathochromaffin/CgA axis under normal and physiopathological conditions. (Endocrinology 154: 3353-3365, 2013) 
T he multifunctional 49-kDa protein chromogranin A (CgA), the index member of the chromogranin/secretogranin family, is stored in secretory granules of various normal and neoplastic neuroendocrine cells, neurons, granulocytes, keratinocytes, and cardiomyocytes (1) (2) (3) . The wide spectrum of its biological and physiopatho-logical activities ranges from systemic to intracellular levels (2) .
Circulating CgA (normal values 0.5-2 nM) (2) represents a useful marker for neuroendocrine tumors and cardiorenal diseases (4 -6) . Importantly, it is also an index of the sympathoadrenal neuroendocrine (SAN) activity, resulting from both the adrenal medulla and the peripheral autonomic nervous system (7) . Accordingly, high plasma CgA levels are observed in patients with perturbed homeostatic cardiocirculatory conditions, such as essential hypertension and heart failure (HF) (6, 8 -10) . In addition, circulating levels of the CgA-derived peptide catestatin (CTS; CgA352-372) decrease in patients with essential hypertension and in normotensive subjects with a family history of hypertension (11) . Circulating CgA increases under conditions of stress-elicited SAN overactivation, which are particularly evident in HF. Plasma CgA concentrations are increased up to 10 -20 nM (500 -1000 ng/ mL) in chronic HF patients, which significantly parallel the severity of the cardiac dysfunction, representing an independent predictor for mortality (9, 10) .
A close and independent association between increased plasma CgA levels (CgA Ͼ 6.6 nmol/L) and adverse outcome was observed in acute destabilized HF patients (12) . These studies also showed that human CgA is produced by the ventricular myocardium, is colocalized with brain natriuretic peptide in ventricular cardiomyocytes and strongly correlates with brain natriuretic peptide plasma concentrations in chronic HF patients.
A close and independent association between CgA levels and adverse outcome was also documented in patients with acute coronary syndromes (13) (14) (15) , whereas Rosjo et al (16) have suggested a possible relation of CgA to the ischemia condition per se.
No information regarding the effects exerted by fulllength CgA on the heart and the factors that regulate its myocardial production are presently available. A particular question that needs to be addressed in clarification of the CgA role in these pathological conditions is to which extent the clinical cardiocirculatory role of CgA depends on its function as a precursor of biologically cardioactive peptides. Indeed, besides its essential intracellular role in the formation of secretory granules and sequestration of hormones in neuroendocrine cells (17, 18) , CgA can also play a variety of extracellular functions that are tightly regulated by intragranular and extracellular proteolytic processing. Proteolysis can be triggered in a tissue-specific manner by prohormone convertase 1 and 2, furin, cathepsin-L, plasmin, and thrombin, resulting in various biologically active fragments (19 -21) . These include the Nterminal vasostatin-I (VS-I; CgA1-76) and vasostatin-II (CgA1-113) involved in the regulation of vascular tension, endothelial permeability, heart contractility, and native immunity; CTS, which in addition to its antihypertensive properties, also regulates catecholamine secretion with consequent inhibition of its target, the nicotinic acetylcholine receptor, thus limiting further catecholamine release (2) .
In the rat heart, in addition to intact CgA and larger C-terminal fragments, 4 vasostatin-containing peptides were identified, ie, CgA4 -113, CgA1-124, CgA1-135, and . This represents a significant biochemical counterpart of the morphological intracardiac detection of CgA in the rodent heart [nonadrenergic myoendocrine atrial cells containing atrial natriuretic peptide (23); atrial and ventricular Purkinje fibers containing the calcium channel 1E subunit (24) ]. Very recent evidence showed that intracellular cleavage of CgA at its highly conserved C terminus can also give rise to 3 serpinin peptides, ie, serpinin (Ala26Leu), pyroglutaminated-serpinin (pGlu23Leu) and serpinin-Arg-Arg-Gly (Ala29Gly) (25) . The first 2 forms, also expressed in the rat heart, have cardioactive properties (26) , inhibit oxidative stress-induced cell death, and promote endocrine secretory granule biogenesis (27) .
Our understanding was enriched by the discovery that the CgA-derived peptides VS-I (28 -34), CTS (35) (36) (37) , and pGlu-serpinin (26) exert relevant direct cardiac actions on perfused heart and papillary muscle preparations. On the rat heart, VS-I, its corresponding homologous fragment, rat CgA1-64, and CTS depress myocardial contractility/ relaxation and counteract the isoproterenol (Iso)-induced positive inotropism as well as the endothelin-1 (ET-1)-induced coronary constriction. Moreover, both VS-I and CTS cardioprotect against ischemia/reperfusion injury [VS-I (38); CTS (39) ]. In particular, CTS variants differentially regulate infarct size after a period of regional ischemia, showing Gly364Ser (GS-Cts) the highest cardioprotective potency (40) . Based on this cardiac physiopharmacological, morphological, and biochemical evidence, we hypothesized that both VS-I and CTS may be viewed as new cardiocirculatory counterregulators in zero steady-state error homeostasis, particularly under intense excitatory stimuli, eg, SAN-induced myocardial stress (eg, hypertensive myocardiopathy) (41) . However, nothing is known regarding the stimuli and the spatiotemporal events implicated in their proteolytic formation.
We here investigated whether and to what extent the full-length CgA exerts a direct influence on the heart performance and, at the same time, may be subjected to stimulus-elicited intracardiac processing. Using normotensive and hypertensive rats, we evaluated the following: 1) the direct myocardial and coronary effects of full-length CgA on isolated and Langendorff-perfused rat heart; 2) the sig-nal-transduction pathway [AkT/nitric oxide synthase (NOS)/nitric oxide (NO)/cGMP/ protein kinase G (PKG)] involved in its action mechanism; and 3) CgA intracardiac processing after ␤-adrenergic (Iso)-and ET-1-dependent stimulation.
Materials and Methods

Animals
Male Wistar rats (Harlan Laboratories, Udine, Italy), weighing 180 -250 g, aged 18 weeks, spontaneously hypertensive rats (SHR) and their normotensive controls, and Wistar Kyoto (WKY) (Harlan Laboratories) were used. Animal care, the killing of the animals, and experiments were in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication number 85-23, revised 1996).
Drugs
Full-length recombinant CgA was prepared by expression of the human CgA cDNA in Escherichia coli cells following standard procedures. The ␤1-adrenergic receptor agonist, Iso; vasoconstrictor, ET-1; selective endothelial nitric oxide synthase
; PKG inhibitor KT5823; destroyer of endothelium functionality, and Triton X-100 were purchased from Sigma Chemical Co (St Louis, Missouri). All drug-containing solutions were freshly prepared before experimentation.
HiTrap N-hydroxysuccinimide-activated High Performance column was from GE Healthcare Biosciences (Pittsburgh, Pennsylvania).
Antibodies
Antihuman VS-I monoclonal antibody (mAb) 5A8 (epitope CgA53-57), cross-reactive with mouse, was produced as described previously (42) . The ELISA assay-mouse monoclonal antibody B4E11 (against CgA68 -71 epitope) was prepared as described (43, 44) . Rabbit anti-CgA polyclonal antisera were raised in rabbits by immunization with full-length CgA or CgA410 -439. A rabbit antiserum against the C-terminal residues 437-439 (anti-RRG) was prepared by preadsorption of the antiCgA410 -439 serum on a chromatographic column bearing the peptide 410 -436 (to remove anti-410 -436 antibodies). Phosphorylated (p)-Akt, Akt, p-eNOS, eNOS, phosphorylated nNOS (p-nNOS), and neuronal nitric oxide synthases (nNOS) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, California) ( Table 2 ).
Isolated heart preparation
Rats were anesthetized by ip ethyl carbamate (2 g/kg per rat). Hearts were rapidly excised and immediately transferred in icecold buffered Krebs-Henseleit solution (KHs) for immediate aorta cannulation through a glass cannula. Retrograde perfusion was conducted at constant flow rate (12 mL/min). To avoid fluid accumulation, the apex of the left ventricle (LV) was pierced. A water-filled latex balloon, connected to a pressure transducer (BLPR; WRI, Inc, Sarasota, Florida), was inserted through the mitral valve into the LV to allow cardiac mechanical parameters recording. A second pressure transducer located above the aorta recorded coronary pressure (CP). The perfusion solution consisted of a modified nonrecirculating KHs containing (in millimoles) NaCl 113, KCl 4.7, NaHCO 3 25, MgSO 4 1.2, CaCl 2 1.8, KH 2 PO 4 1.2, glucose 11, mannitol 1.1, and Na-pyruvate 5 (pH 7.4; 37°C; 95% O 2 /5% CO 2 ). Hemodynamic parameters were assessed using PowerLab data acquisition system and analyzed using Chart software (ADInstruments, Oxford, United Kingdom).
Basal conditions
As previously detailed (35) , inotropism was evaluated in terms of LV pressure (LVP; mmHg, index of contractile activity), maximal value of the first LVP derivative [ϩ(LVdP/dT) max; in mmHg/sec, index of maximal LV contraction rate], rate pressure product (mmHg beats min Ϫ1 ), and time to peak (seconds). Lusitropism was assessed on the basis of the maximal rate of LVP decline [Ϫ(LVdP/dT) max; mmHg per second], the T to ϪT ratio [obtained by ϩ(LVdP/dT) max/Ϫ(LVdP/dT) max], half-time relaxation (seconds), and end diastolic ventricular pressure (mmHg). Coronary vasomotility was evaluated in terms of CP (mmHg), whereas heart rate (HR) changes (beats per minute) were used to estimate chronotropism.
CgA-stimulated preparations
Twenty minutes after stabilization with KHs alone, dose-response curves were generated by perfusing each cardiac preparation with KHs supplemented with exogenous CgA increasing concentrations (1 pM to 16 nM) for 10 minutes (n ϭ 7). Repetitive exposure of each heart to a single CgA concentration (4 nM) revealed absence of desensitization (data not shown; n ϭ 5). Previous analyses showed that CgA remains stable in the perfusate for throughout the experimental period (data not shown).
NO pathway involvement
To evaluate the involvement of the NO pathway in the CgA action mechanism, Wistar rat hearts were stabilized for 20 minutes with KHs and perfused for 10 minutes with CgA (4 nM); then the CgA effect was washed out with KHs and, after returning to control conditions, hearts were perfused with KHs containing PTIO (10 M) or L-NIO (10 M) or ODQ (10 M) or KT5823 (0.1 M). Subsequently cardiac preparations were exposed to KHs enriched with CgA plus each of these inhibitors (n ϭ 6 for each group).
Endothelial contribution
To evaluate its putative implication, the coronary endothelium was made dysfunctional by a brief perfusion with Triton X-100 (1:200 dilution) administered after 30 minutes of equilibration. Triton X-100 infusion was equivalent to 1% of the flow rate delivered into the Krebs-Henseleit buffer immediately above the aorta for 1 second (36) . Triton X-100 treatment induced an early CP increase (37 Ϯ 5.1 mm Hg), which returned almost to control values after 20 minutes. LVP significantly decreased during Triton X-100 treatment and then completely recovered within 20 minutes. Subsequently, the hearts were perfused for 25 minutes with normal KHs before examining the CgA-induced coronary actions, as described above. To verify the Triton X-100 effectiveness, the CgA-exposed hearts were washed out with KHs and then perfused for 10 minutes with bradykinin (100 nM). Only the hearts in which bradykinin did not change CP were included in the analysis (45) (n ϭ 6).
cGMP and cAMP Measurements
Acid-frozen heart extracts (200 -300 mg of ventricle tissues comprising endocardial and myocardial tissue) with and without CgA perfusion were treated with 6% trichloroacetic acid at 0°C and centrifuged at 10 000 ϫ g for 10 minutes. The supernatant was extracted 3 times with 3 mL of diethyl ether saturated with water, and the aqueous phase was collected and stored at Ϫ80°C. cGMP and cAMP concentrations were measured using a commercial enzyme immunoassay (Biotrak EIA system; Amersham Biosciences, Piscataway, New Jersey) (n ϭ 4).
Western blotting analysis
Human umbilical vein endothelial cells (HUVECs) and cardiac ventricles were used to evaluate differences in protein phosphorylation. HUVECs were purchased from American Type Culture Collection (Manassas, Virginia) and grown in endothelial growth medium-2-supplemented medium (Lonza, Gaithersburg, Maryland) containing penicillin and streptomycin at 37°C and 5% CO 2 . HUVEC cells were treated with CgA (4 nM) for 15 minutes and then collected, washed twice with PBS, and lysed in ice-cold radioimmunoprecipitation assay buffer (Sigma-Aldrich, Milan, Italy). Cardiac ventricles obtained after perfusion with KHs alone or with a single concentration of CgA (4 nM) or with Triton X-100 alone or with Triton X-100 plus CgA were used. Samples were homogenized in ice-cold radioimmunoprecipitation assay buffer (Sigma-Aldrich) containing a mixture of protease inhibitors (1 mmol/L aprotinin, 20 mmol/L phenylmethylsulfonyl fluoride, and 200 mmol/L sodium orthovanadate). Then homogenates were centrifuged at 200 ϫ g for 10 minutes at 4°C for debris removal. Protein concentration was determined using a Bradford reagent according to the manufacturer (SigmaAldrich). Equal amounts of proteins were separated on 8% SDS-PAGE gels (for p-eNOS, eNOS, p-nNOS, nNOS, 60 g) or on 10% SDS-PAGE gels (for p-Akt and Akt, 40 g), transferred to polyvinyl difluoride membranes, blocked with nonfat dried milk, and incubated overnight at 4°C with a polyclonal rabbit anti-p-eNOS antibody or a polyclonal goat anti-p-nNOS antibody or with a polyclonal rabbit anti-p-Akt antibody (Santa Cruz Biotechnology, Santa Cruz, California) diluted 1:1000 in Tris-buffered saline and 0.2% Tween 20 containing 5% nonfat dry milk. Antirabbit and antigoat peroxidase-linked secondary antibodies (Santa Cruz Biotechnology) were diluted 1:2000 in Tris-buffered saline and 0.2% Tween 20 containing 5% nonfat dry milk. Polyclonal rabbit anti-eNOS and anti-Akt and polyclonal goat anti-nNOS antibodies were used as loading controls (Santa Cruz Biotechnology) (n ϭ 4 for each group).
Immunodetection was performed using an enhanced chemiluminescence kit (ECL PLUS; Amersham). Autoradiographs were obtained by exposure to X-ray films (Hyperfilm ECL; Amersham). Immunoblots were digitalized and the densitometric analysis of the bands was carried out using NIH IMAGE 1.6 (National Institutes of Health, Bethesda, Maryland) for a Macintosh computer based on 256 Gy values (0 ϭ white; 256 ϭ black).
CgA intracardiac processing
CgA processing was evaluated by using a mouse monoclonal primary antibody (5A8) (42) directed against the VS-I sequence. Hearts from Wistar, WKY, and SHR rats were subjected to physical perfusion-dependent hemodynamic stress (20 min, 60 min, 120 min perfusion) and to chemical stimulation (exposure to Iso 1 nM, 100 nM, and ET-1 10 nM). The perfusate was collected and stored for the analysis. Hearts were then homogenized as previously described and separated on 10% SDS-PAGE gels (50 g of total proteins). The immunodetection was performed as described before (n ϭ 4 for each group), by using 4 different hearts for each group.
Affinity chromatography
Anti-VS-I antibody (mAb 5A8) was coupled to a HiTrap Nhydroxysuccinimide-activated HP column (GE Healthcare) in accordance with the manufacturer's protocol. The coupling buffer composition was 0.2 M NaHCO 3 and 0.5 M NaCl (pH 8.3); after 30 minutes of antibody incubation, 0.5 M ethanolamine plus 0.5 M and NaCl (pH 8.3) were used as the washing buffer, alternating 3 times with 0.1 M acetate, 0.5 M NaCl (pH 4.0) to deactivate any excess active groups that have not coupled to the ligand and wash out the nonspecifically bound ligands. Then 0.05 M Na 2 HPO 4 (pH 7.0) was added to adjust the pH. Tris/HCl 75 mM (pH 8.0) was then applied. Samples of rat heart protein extracts treated as previously described were then applied to the equilibrated affinity column and eluted with Tris/HCl 75 mM (pH 8.0). The elution buffer containing 100 mM glycine (pH 2.0) was then allowed to flow through the column, and every 0.5-mL samples were collected into test tubes containing neutralization buffer (fractions collected were denoted in numerical order as fractions 1, 2, 3, etc). One mole of Tris buffer was used as the neutralization buffer. All samples and buffers were then kept at 4°C. Immunodetection was performed on purified extracts by using a mouse monoclonal primary antibody (5A8) as described before (n ϭ 4 for each group).
Sandwich ELISAs of CgA
CgA was detected, in both Wistar and SHR hearts, in the perfusion medium represented by KHs alone, plus Iso 1 nM, or plus CgA 4 nM inflowing to and outflowing from the cardiac preparation. For this purpose 3 sandwich ELISAs were used, ie, CgA capture with mAb B4E11 and detection with rabbit antisera against full-length CgA (assay 1) or anti-RRG (assay 2) or CgA410 -439 (assay 3). The assays were performed as described previously (9) . Validation studies showed that assay 1 detects full-length CgA plus fragments lacking the region 410 -439; assay 2 detects full-length CgA but not fragments lacking the region 410 -439; and assay 3 detects the full-length CgA plus fragments lacking the region 437-439 (RRG) (n ϭ 4 for each group).
Statistics
Data are expressed as the mean Ϯ SEM. Because each heart represents its own control, the statistical significance of differences within a group was assessed using the ANOVA test (P Ͻ .05). Comparison between groups was made by using a 1-way ANOVA followed by the Bonferroni correction for post hoc Student's t tests; statistical significance was concluded at P Ͻ .05.
Results
Basal conditions
Cardiac parameters, obtained after 20 minutes of equilibration, of Wistar, WKY, and SHR rats are shown in Table 1 . Endurance and stability of the preparations, analyzed by measuring the performance variables every 10 minutes, showed that each heart was stable up to 180 minutes.
Direct actions of exogenous full-length CgA on Wistar rat hearts
Previous works revealed that CgA-derived peptides, such as human recombinant CgA1-78 (VS-I), rat CgA1-64, CTS, and serpinin modulate the cardiac performance (6, 26, 28 -32) . To evaluate whether the exogenous fulllength protein affects basal cardiac parameters, heart preparations were exposed to increasing CgA concentrations after 20 minutes of stabilization. Because the CgA effect remained stable for 15-20 minutes, cardiac parameters were measured after 10 minutes. CgA induced negative inotropic [significant reduction of LVP and ϩ(LVdP/ dT) max from 100 pM to 4 nM] and lusitropic [significant reduction of Ϫ(LVdP/dT) max and increased T/Ϫt at 100 pM, 1 nM, and 4 nM] effects (Figure 1 ). CgA also induced coronary vasodilation at 1 and 4 nM concentrations, without influencing HR (Figure 1 ). Both the inotropic and lusitropic effects disappeared at higher concentrations (10 -16 nM) (Figure 1 ), pointing to a bell-shaped doseresponse curve.
Involvement of the NO pathway
In the mammalian heart, the NOS-NO-cGMP-PKG signaling modulates the beat-to beat and the medium-and long-term contractile performance (35) . To evaluate Abbreviations: EDVP, end diastolic ventricular pressure; RPP, rate pressure product. Values were calculated as means Ϯ SD (n ϭ 10 for each group). (Figure 2A ). The involvement of NO signaling was confirmed by the observation that CgA (4 nM) induces the phosphorylation of Akt, a well-known upstream activator of the NO pathway ( Figure 2B ) and eNOS in ventricle extracts ( Figure  2C ) and HUVECs ( Figure 2E ). The functional endothelial destruction by Triton X-100 abolished both Akt and eNOS phosphorylation, pointing to an important contribution of the endothelium in the mechanism of action of CgA (Figure 2, B and C) . Contrarily, CgA did not induce nNOS phosphorylation ( Figure 2D ).
cAMP/cGMP involvement
To verify cGMP involvement in the mechanism of action of CgA, intracellular cGMP levels were measured in extracts of Wistar rat hearts treated with CgA (4 nM). A significant increase was observed, in agreement with the well-known cGMP-induced negative inotropism. In contrast, CgA did not change cAMP levels ( Figure 2F ).
Exogenous full-length CgA effects on WKY and SHR hearts
Targeted ablation of the CgA gene makes CgA-knockout mice hypertensive and hyperadrenergic, with accompanied cardiac enlargement, increases reactive oxygen species production and consequent NO depletion (46) . To verify CgA influence in the presence of hypertensive conditions, the effects of the full-length protein were tested on SHRs, an animal model that mimics the human hypertensive pathology (47) , and on their normotensive counterparts (WKY). In both SHR and WKY hearts, CgA induced relevant negative inotropic and lusitropic effects, even at concentrations as low as 1 pM and up to 4 nM, as indicated by the decrease of LVP and ϩ(LVdP/dT) max, and by the decrease of Ϫ(LVdP/dT) max and the increase of T/Ϫt ( Figure 3A) . These effects disappeared when higher CgA concentrations (10 -16 nM) were used ( Figure  3A) . In both SHR and WKY hearts, CgA did not affect CP and HR ( Figure 3A) .
NO signaling in SHR hearts
It is reported that the pathophysiology of hypertension involves complex multiple vascular effectors including reactive oxygen species and NO. Reactive oxygen species may directly alter vascular function or cause changes in the vascular tone by several mechanisms including altered NO bioavailability or signaling (48) . To verify the involvement of the NO pathway in the CgA-induced cardiac effects on the hypertensive SHR, CgA-perfused SHR and WKY hearts were subjected to Western blotting and ELISA analyses. We observed increased Akt and eNOS phosphorylation in both WKY and SHR hearts (Figure 3 , B and C) and increased intracellular cGMP levels ( Figure 3D ). 
Detection of CgA in cardiac perfusates
To verify whether CgA is released by the heart, cardiac perfusates from both Wistar rats and SHRs were collected after perfusion with either KHs alone or plus CgA or plus Iso for 10 minutes. Perfusates were then analyzed by using Western blotting to detect VS-I and 3 different ELISAs capable to detect full-length CgA (assay 1), full-length CgA plus fragments lacking the C-terminal region 436 -439 (RRG) (assay 2), and full-length CgA plus fragment lacking the entire C-terminal (assay 3). Neither full-length CgA nor its fragments were detected in the perfusate of hearts from both Wistar rats and SHRs treated with either KHs alone or Iso (1 nM) (Figure 4 , A and C, respectively). In addition, the perfusate of both Wistar and SHR hearts exposed to full-length CgA (4 nM) was found to contain a protein concentration that was lower than that present in the perfusion medium ( Figure 4B ). The lower levels of fulllength CgA in the perfusate were unlikely dependent on fragmentation because similar results were obtained with assays capable to also detect fragments. More likely, a fraction of CgA was bound in the heart tissue. Western blotting analysis of the cardiac perfusate revealed that, under both unstimulated and stimulated conditions, neither Wistar nor SHR hearts release VS-I.
Intracardiac CgA processing
After the first evidence that intracardiac CgA may be subjected to proteolytic processing, generating smaller peptides, including vasostatins (22), we explored whether, in the presence of physical and chemical stimulation, cardiac CgA undergoes proteolytic cleavage. Western blotting analyses with mAb 5A8 revealed, in nonperfused hearts, the presence of high molecular mass bands from 50 to 100 kDa, which include the intact rat CgA. It has been reported by Glattard et al (22) that a major broad immunoreactive band at an apparent molecular mass of 80 -50 kDa is present in rat heart extracts. This large band includes the apparent molecular mass of intact rat CgA (with and without posttranslational modifications, such as glycosylations) as well as several large N-terminal-derived fragments and aggregates of CgA that resist SDS PAGE (49) . Such a broad pattern is due to the presence of glutamic acid clusters [eg, CgA (216 -228)], known to modify the electrophoretic migration of CgA [CgA (1-448), 48 kDa] with the apparent molecular mass of 80 kDa (50, 51) . This major broad immunoreactive band is reduced in hearts perfused for 20 minutes and stimulated by Iso (1 and 100 nM) or ET-1 (10 nM). Other bands corresponding to 70-, 66-, 50-, 46-, 40-, 37-, and 30-kDa fragments were detected in cardiac ex- tracts of Wistar, WKY, and SHR ( Figure 5A ). Because these bands were detected with the mAb 5A8 (epitope CgA53-57), they likely correspond to fragments containing the N-terminal region, suggesting that fragmentation started from the C-terminal end. Furthermore, low-molecular-mass bands (10 -30 kDa) were detected in Wistar, but not in nonperfused heart extracts ( Figure 5A ). To analyze the intracardiac processing of CgA, we decided to evaluate 2 bands having different molecular masses (50 and 10 kDa bands). The densitometric analysis of these bands revealed increased proteolysis and the generation of shorter fragments in hearts stimulated by Iso or ET-1 (Figure 5B) . This suggests that low-molecular-weight fragments, likely corresponding to the VS-I region, were generated.
Affinity chromatography purification and subsequent Western blotting analyses with mAb 5A8 of purified cardiac extracts confirmed the presence of VS-I in extracts from stimulated hearts of both Wistar rats and SHRs but not in the nonperfused counterparts ( Figure 5C ). Of note, only qualitative information can be obtained by affinity chromatography because it is possible that CgA forms molecular aggregates, and this prevents antibody recognition, allowing only the identification of low-molecular-weight fragments, such as VS-I.
Discussion
In this work, for the first time, we show that exogenous full-length human CgA, at concentrations close to its physiological circulating levels (1 nM), affects the rat heart performance by inducing significant myocardial contractile (inotropic), relaxing (lusitropic), and coronary (vasomotive) effects. These actions are mediated by an endothelium-dependent mechanism that involves phosphatidylinositol 3-kinase-NO signaling. Furthermore, we demonstrated in the rat heart that intracardiac CgA is proteolytically processed to generate smaller fragments, including the cardioactive and vasoactive VS-I, and that this processing is enhanced by chemical (Iso or ET-1) stimulation.
Direct actions of full-length CgA on Wistar rat and SHR hearts
Exogenous full-length CgA induces negative inotropic and lusitropic effects at 0.1-4 nM concentrations and a significant coronary dilation at 1-4 nM (preceded by vasoconstriction at lower concentrations). These actions disappear at higher concentrations (10 and 16 nM), generating a bell-shaped (or U shaped) curve. Various biological responses [eg, endostatin induced antitumor activity (52), interferon-␣ mediated inhibition of angiogenesis (53)], including the biphasic influence of CgA on blood pressure levels and catecholamine secretion in mice (54) exhibit U-shaped concentration/response curves. The mechanism underlying this behavior is unknown: one possibility is that this phenomenon reflects counterregulatory mechanism activated at high concentrations or to structural changes of CgA (eg, changes in the quaternary structure), considering that CgA may exist as a monomer or a dimer at physiological pH (55) . Further work is necessary to address this issue.
Of note, the bioactive concentration of full-length CgA is close to that found in human plasma under normal conditions. These findings suggest that the intact prohormone is able to directly depress cardiac contractility and to induce coronary dilation, like its vasostatins-and CTS-derived fragments; remarkably, these effects are exerted at lower and more physiologically relevant concentrations. Notably, exogenous CgA exerts more potent negative inotropic and lusitropic effects in SHR rats compared with normotensive young Wistar rats. The higher responsiveness of SHR hearts to exogenous CgA may be consistent with the elevated sensitivity shown by the SHR heart toward inhibitory hormones (ie, angiotensin II, atrial natriuretic factor, etc) (56) . This phenomenon has been attributed to the activation of several inhibitory pathways, including the overexpression of a Gi regulatory protein implicated in the reduced vascular tone and impaired myocardial functions in the presence of hypertension (56) . Importantly, exogenous CgA elicited different coronary effects in young Wistar rats and SHRs. In fact, in the former CgA (1 and 4 nM) exerted vasodilation, being, instead, noneffective in SHRs. The putative mechanisms underpinning this different response are discussed below. Of note, CgA null mice are hypertensive (11) , and circulatory CgA protein levels are increased in human hypertension (8) . Thus, the negative inotropic effect elicited by full-length CgA possibly represents a compensatory mechanism for increased blood pressure.
NO/cGMP/PKG involvement
Our results show that, like VS-I and CTS, exogenous full-length CgA exerts its cardiodepression through an endothelium-mediated NO/ cGMP/PKG mechanism, pointing to a common signal-transduction pathway. In fact, the evidence obtained with whole organ and isolated cell (cultured endothelium) preparations suggests that intact CgA first encounters the endothelial barrier and locally triggers an endothelial phosphatidylinositol 3-kinase/Akt-dependent NO cascade responsible for the ultimate effects on the myocardiocyte and coronary smooth muscle cells. This endothelium-mediated mechanism is compatible with the large dimensions of the protein that may prevent it to reach the cell targets subjacent to the endothelium.
The vascular endothelium is an important source of eNOS-produced NO (57) . To define the contribution of NOS-generated NO in CgA signaling, we demonstrated in ex vivo experiments that isoform-specific chemical inhibition of eNOS abolished CgA cardioactivity. In agreement with these functional observations, we found in perfused hearts of both Wistar rats and SHRs, as well as in HUVECs, that CgA exposure elicits eNOS phosphorylation. Accordingly, in both normotensive and hypertensive hearts, CgA-induced actions require an NO-obligatory mechanism. NO contributes to both the beat-to-beat and the long-term control of contractile performance (57) . Cardiac NOS-produced NO exerts tonic negative modulation of contractility through soluble guanylate cyclase-PKG signaling, thereby reducing L-type Ca 2ϩ current and phosphorylating troponin I (58) . At the same time, NOcGMP-PKG activation also contributes to modulate relaxation by inhibiting PLB phosphorylation, thus attenuating sarcoplasmic reticulum Ca 2ϩ reuptake (59).
Consistent with this knowledge, CgA was found to depress relaxation in both Wistar rats and SHRs. Interestingly, in contrast to the similarity of its NO-induced myocardial actions, the different coronary response to full-length CgA observed in young Wistar rats and SHRs needs to be clarified by a mechanistically oriented study. However, it is tempting to hypothesize that this lack of responsiveness in the hypertensive condition may be attributed to a reduced NO availability/capability in regulating SHR basal coronary flow caused by a decrease of shear stressstimulated NO (60, 61) . In fact, an impaired endothelium-dependent vasodilation in SHRs has been related to structural changes at the level of myocardial arteries and/or a reduction in both capillary density and eNOS expression (59) .
CgA detection and processing
Analysis of the cardiac perfusates indicated that exogenous CgA is not cleaved by the heart; thus, the myocardial effects elicited by the protein can be attributed to the full-length molecule, excluding the involvement of derived fragment, including VS-I.
The global peptidomic approach by Gupta et al (62) demonstrates the complexity of diverse neuropeptides present in human secretory vesicles for cell-cell communication, including CgA-derived fragments. In the present study, we observed that the normal rodent heart, if physically and chemically stimulated, generates and processes CgA into a number of smaller fragments. Such processing also occurs in the diseased SHR heart. Western blotting analyses of cardiac extracts from Wistar and WKY rats and SHRs revealed the presence of major immunoreactive bands of 80 -50 kDa. Because the 5A8 antibody used for immunoblotting is able to bind a vasostatin domain (epitope CgA53-57), we hypothesize that these bands correspond to full-length intracardiac CgA and truncated fragments lacking the C-terminal region. Our observations agree with the previous evidence of Figure 5 . A, Immunoblots showing intracardiac CgA processing in extracts of Wistar, WKY, and SHR hearts. NP, nonperfused heart, 20 minutes of perfusion; Iso (1 nM); Iso (100 nM); ET-1 (10 nM). B, Densitometric analysis of CgA band (ϳ50 kDa) and VS-1 band (ϳ10 kDa). C, Immunoblots of cardiac extracts purified by affinity chromatography for VS-I detection in nonperfused hearts (NP) with 20 minutes of perfusion, Iso (100 nM), and ET-1 (10 nM). Immunodetection was performed by using a mouse monoclonal primary antibody (5A8).
Glattard et al (22) that the rat heart produces CgA and processes it to give rise to several fragments including vasostatin-containing peptides. These findings are also consistent with CgA identification in amphibian (63) and mammalian heart [rat atrial secretory granules (23) and conduction system (24) ] in the mouse (64) and in human ventricle (10) .
Interestingly, our study showed that physical (perfusion) and chemical (Iso and ET-1) challenges can induce cardiac CgA proteolytic processing into shorter fragments. Such processing, which occurs in both normal and diseased hearts, is particularly enhanced by adrenergic (Iso 100 nM) and ET-1 (110 nM) stimulation. In both cases, compared with the untreated counterparts, the full-length/ large fragments are reduced, whereas short N-terminal fragments of a size corresponding to that of VS-I are increased.
With respect to Wistar rats, qualitative variations observed in SHR processing could be due to metabolic changes occurring in pathological conditions, such as hypertension. In fact, it has been reported that in the presence of different diseases, including hypertension, heart failure progression is accompanied by an increase in proteolytic activities (65) . This suggested a nonspecific CgA degradation into amino acids, perhaps through shunting into lysosomes upon stimulation. However, the exact mechanism responsible for the processing remains to be clarified.
The detected prohormone convertase 1/3, prohormone convertase 2, and carboxypeptidase H/E in the rat heart might be involved in CgA maturation process (19) . Intragranular and extracellular CgA processing in chromaffin granules from bovine adrenal medulla indicates that it starts at both the N terminus and the C terminus of the protein (19) . Among the major proteolytic cleavage sites involved, the bond 64 -65, present in the N-terminal moiety of CgA and included in the vasostatin sequence, is highly conserved (19) and is implicated in cardioactive peptide formation (29) .
The demonstration that the heart processes CgA-producing vasostatin-containing peptides strongly supports our hypothesis that these fragments play a role in the autocrine/paracrine regulation of myocardial (inotropic/ lusitropic) and coronary (vasomotility) function, exerting, at the same time, strong antiadrenergic and antiendothelin actions (28, 29, 41) . This new information may expand the classical concept of the heart as an endocrine organ, particularly in relation to the adrenergically elevated outflow characteristic of its stressed state.
Conclusions
This study, together with our previous data on the direct myocardial and coronary effects exerted by the CgA-derived peptides VS-I, CTS, and serpinin, provides for the first time at the cardiovascular level a conceptual link between the systemic and intracardiac actions of full-length CgA and its derived peptides. This information represents the premise for mechanistic studies aimed to decipher the role of CgA in cardiocirculatory homeostasis in relation to the spatiotemporal orchestration of its actions at systemic and heart levels.
